Side-by-side · Research reference

EpitalonvsTesofensine

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticDraft8/37 cited

BPhase 3Draft10/40 cited

Epitalon

Pineal bioregulator · Telomerase activator

5–10 mgPer cycle doseKhavinson 2003

HumanMechanisticKhavinson 2003

HoursHalf-life (est)

SQ or IM · Abdomen · Daily for 10–20 days

Tesofensine

SNDRI · Phase 3 obesity candidate

0.25–0.5 mgDaily doseAstrup 2008

9.2 kgWeight ↓ (24 wk)Astrup 2008

Phase 3Evidence levelAstrup 2008

Oral · Once daily morning

01Mechanism of Action

Parameter

Epitalon

Tesofensine

Primary target

Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003

Serotonin / norepinephrine / dopamine transporters (SERT / NET / DAT)Astrup 2008

Pathway

Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003

Triple monoamine reuptake inhibition → ↑synaptic 5-HT, NE, DA → appetite suppression + thermogenesisAstrup 2008

Downstream effect

Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003

Strong appetite suppression, mild thermogenic effect, weight lossAstrup 2008

Feedback intact?

—

Origin

Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003

Small molecule developed by NeuroSearch (Denmark) for CNS indications, repurposed for obesityAstrup 2008

Antibody development

—

02Dosage Protocols

Parameter

Epitalon

Tesofensine

Standard dose

5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003

Anecdotal community protocol. Russian clinical literature uses similar cycling.

0.25–0.5 mg / dayAstrup 2008

Frequency

Once daily during a cycle

Once daily, morning

Lower / starter dose

2.5 mg / day

0.125 mg / day

Evidence basis

In-vitro telomerase + Russian clinical trialsKhavinson 2003

Phase 2b + ongoing Phase 3Astrup 2008

Duration

10–20 day cycles, 1–2× per year

24 weeks per studied cycle

Reconstitution

Bacteriostatic water

—

Timing

Pre-sleep preferred (pineal alignment)

Morning to avoid sleep disruption

Half-life

Hours (estimated)

~9 days (very long)

Form

—

Oral capsule

04Side Effects & Safety

Parameter

Epitalon

Tesofensine

Injection site reaction

Mild irritation

—

Sleep architecture

Improved subjective sleep quality (anecdotal)

—

Cancer risk

Theoretical via telomerase activation in pre-malignant cells

—

Long-term safety

Limited Western RCT data

—

Pregnancy / OB

Avoid

Contraindicated

Antibody formation

Not reported

—

Heart rate / BP

—

Dose-dependent ↑ HR + BPAstrup 2008

Insomnia

—

Dose-related; mitigate with morning timing

Dry mouth

—

Common

Nausea

—

Common

Mood changes

—

Anxiety / agitation possible

Cardiovascular events

—

Phase 3 trial monitoring; not yet FDA-cleared

Absolute Contraindications

Epitalon

·Pregnancy / breastfeeding
·Active malignancy or pre-malignant state

Tesofensine

·Pregnancy / breastfeeding
·Severe cardiovascular disease
·Concurrent MAOI use

Relative Contraindications

Epitalon

·Family history of cancer

Tesofensine

·Hypertension
·Anxiety disorder
·Insomnia

05Administration Protocol

Parameter

Epitalon

Tesofensine

1. Reconstitution

Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.

Oral capsule (investigational; not commercial).

2. Injection site

SQ — abdomen preferred. Rotate sites.

Swallow whole with water, morning only.

3. Timing

Pre-sleep preferred to align with pineal axis.

Morning to mitigate insomnia. Do not dose evening.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

Room temp ≤25 °C, dry place.

5. Needle

29–31G, 4–8 mm insulin syringe.

Monitor BP + HR + mood. Avoid stimulants + MAOIs.